1	Application of Urinary Peptide-Biomarkers in Trauma
2	Patients as a Predictive Tool for Prognostic Assessment,
3	Treatment Interventions, and Intervention Timing:
4	Prospective Nonrandomized Pilot Study
5	
6	Gökmen Aktas ¹ *, Felix Keller ² , Justyna Siwy ³ , Agnieszka Latosinska ³ , Harald Mischak ³ ,
7	Jorge Mayor ¹ , Jan Clausen ¹ , Michaela Wilhelmi ¹ , Vesta Brauckmann ¹ , Stephan
8	Sehmisch ¹ , Tarek Omar Pacha ¹ †
9	¹ Department of Trauma Surgery, Hannover Medical School, Carl-Neuberg St. 1, Hannover,
10	30625, Lower Saxony, Germany
11	² Department of Internal Medicine IV (Nephrology and Hypertension), Medical University of
12	Innsbruck, Anich St. 35, Innsbruck, A-6020, Austria
13	³ Mosaiques Diagnostics GmbH, Rotenburger St 20, Hannover, 30659, Lower Saxony,
14	Germany
15	
16	*Corresponding author: <u>Aktas.Goekmen@mh-hannover.de;</u>
17	Contributing authors: Felix.Keller@i-med.ac.at; siwy@mosaiques-diagnostics.com;
18	latosinska@mosaiques-diagnostics.com; mischak@mosaiques-diagnostics.com
19	MayorRamirez.Jorge@mh-hannover.de;
20	Brauckmann.Vesta@mh-hannover.de; Wilhelmi.Michaela@mh-hannover.de;
21	Sehmisch.Stephan@mh-hannover.de; OmarPacha.Tarek@mh-hannover.de
22	<i>†These authors contributed equally to this work.</i>
23	Abstract

Background: Treatment of severely injured patients represents a major challenge, in part
due to the unpredictable risk of major adverse events, including death. Preemptive
personalized treatment aimed at preventing these events is a key objective of patient
management; however, the currently available scoring systems provide only moderate
guidance. Molecular biomarkers from proteomics/peptidomics studies hold promise for
improving the current situation, ultimately enabling precision medicine based on individual
molecular profiles.

31 Methods: To test the hypothesis that proteomics biomarkers could predict patient outcomes

32 in severely injured patients, we initiated a pilot study involving consecutive urine sampling

33 (on days 0, 2, 5, 10, and 14) and subsequent peptidome analysis using capillary

34 electrophoresis coupled to mass spectrometry (CE-MS) of 14 severely injured patients and

two additional ICU patients. The urine peptidomes of these patients were compared to the

36 urine peptidomes of age- and sex-matched controls. Previously established urinary peptide-

based classifiers, CKD274, AKI204, and CoV50, were applied to the obtained peptidome

data, and the association of the scores with a combined endpoint (death and/or kidney failure

39 and/or respiratory insufficiency) was investigated.

Results: CE-MS peptidome analysis identified 281 peptides that were significantly altered in severely injured patients. Consistent upregulation was observed for peptides from A1AT, FETUA, and MYG, while peptides derived from CD99, PIGR and UROM were consistently reduced. Most of the significant peptides were from different collagens, and the majority were reduced in abundance. Two of the predefined peptidomic classifiers, CKD273 and AKI204, showed significant associations with the combined endpoint, which was not observed for the routine scores generally applied in the clinics.

47 Conclusions: This prospective pilot study confirmed the hypothesis that urinary peptides 48 provide information on patient outcomes and may guide personalized interventions based on 49 individual molecular changes. The results obtained allow the planning of a well-powered 50 prospective trial investigating the value of urinary peptides in this context in more detail.

51 **Keywords:** urine, biomarker, trauma, polytrauma, intensive care, critical care, proteomics,

52 peptides, prediction

53 Background

54 Severe trauma patients represent a significant medical challenge, often requiring intensive 55 care unit (ICU) admission due to the life-threatening nature of their injuries (1). These 56 patients have sustained critical injuries, e.g., car accidents, high-energy trauma or falls from 57 great heights(2). Managing severely injured patients in the ICU involves a multidisciplinary 58 approach(3). The outcome of these patients can be unpredictable given the severity of their 59 injuries(4). Often, despite intensive monitoring and intervention, their condition can 60 deteriorate significantly, become unsustainable, and ultimately result in death due to multiple 61 organ dysfunction syndrome (MODS)(5). 62 When referring to polytraumatized patients, the definition by Muhr and Tscherne is frequently 63 applied (6). However, the term 'polytrauma' is used inconsistently. Therefore, a new definition 64 of polytrauma was recently developed(7). Today, the widely accepted definition, the New 65 Berlin Score, characterizes polytrauma as a significant injury in at least 2 body regions with 66 an abbreviated injury scale (AIS) score of 3 or higher and at least one pathological value for 67 one of the following parameters: age (above 70), hypotension (systolic blood pressure <90 68 mmHg), unconsciousness (Glasgow coma scale (GCS) at the scene <=8), acidosis (base 69 excess <=-6), and coagulopathy (partial thromboplastin time (PTT) >=40/INR >=1.4)(7). 70 Similarly, the definition of 'multiorgan failure' (MOF) has evolved. MOF was redefined in 1992 71 through a consensus conference(8). MOF was no longer defined as a static condition but 72 rather a dynamic and reversible process. Additionally, the classical MOF was replaced with

73 MODS and comprehensively defined. In this definition, MODS is described as the

dysfunction of organs in critically ill patients, which can only be resolved through therapeutic

75 interventions(8).

76	Mortality rates for MODS have improved over time in the US, decreasing from 33-36% in
77	approximately 2010 to 22% in more recent studies(9,10). Of these deaths, 24% are due to
78	cardiovascular events within the first few days of ICU admission(10).
79	Various scoring systems, including the sequential organ failure assessment (SOFA) score
80	and the multiorgan dysfunction (MOD) score, which are common metrics in clinical studies of
81	intensive care medicine, have been developed to assess the severity of organ dysfunction
82	and predict mortality(11). Both systems meet the requirements for describing organ
83	dysfunction. Both SOFA and MOD assess the same six organ systems, but they have
84	practical differences in their calculations(11). The SOFA score is based on the most deviant
85	value within a 24-hour period, while the MOD score uses physiological values measured at
86	the same time every day to avoid capturing momentary physiological changes(11). The acute
87	physiology and chronic health evaluation II (APACHE II) score provides further metrics and is
88	commonly used complimentary to the SOFA score (1). In addition to parameters from
89	individual organ systems, it incorporates the patient's age, current clinical findings, and
90	medical history to make predictions about the likelihood of survival in an intensive care
91	setting(12).
92	The simplified acute physiology score II (SAPS II) allows for assessing the severity of
93	disease in a patient admitted to an ICU and provides information about morbidity(13).
94	Additionally, the score, in combination with the therapeutic intervention scoring system
95	(TISS), can be used to assess the progression of disease severity and the intensity of
96	treatment effort(13).
97	These scores help clinicians evaluate the severity of disease and the intensity of treatment
98	needed, although they do not always account for trauma as the underlying cause of ICU
99	admission.
100	Specifically, the injury severity score (ISS) and the trauma and injury severity score (TRISS)

are widely used. The ISS is calculated by adding the three highest body area values of the

abbreviated injury scale (AIS) squared together(14). The TRISS, introduced in 1981, is a

103 combined index based on the revised trauma score (RTS), ISS, and patient age to predict 104 survival probabilities(14). The results indicate that the TRISS aligns well with expected 105 outcomes and performs favourably compared to other indices, such as the ISS(14). 106 However, these variables may not capture the full complexity of a patient's condition. 107 The revised injury severity classification (RISC) score, introduced in 2003, included not only 108 anatomical injury descriptions but also physiological indicators (e.g., base deficit, 109 haemoglobin, and cardiopulmonary resuscitation)(15). To address some remaining issues, 110 accompanied by the RISC score, the RISC II was developed(15). In addition to other 111 changes, it includes new predictors such as pupil size and reactivity. The RISC-II model 112 outperforms the original RISC, particularly in terms of discrimination, precision, and 113 calibration. It can be used to estimate the risk of death in severely injured patients more 114 effectively. The integration of RISC II into daily intensive care practice, especially as a tool for 115 monitoring patient progress, is challenging due to its complex calculation and the collection 116 of numerous parameters(15,16). 117 In the context of ICU management, advanced laboratory testing and monitoring are crucial. 118 Parameters such as N-terminal pro B-Typ natriuretic peptide (NT-proBNP) and troponin are 119 used to assess cardiac function(17). However, there is a known mutual influence of these 120 parameters in cases of concurrent kidney failure, prompting more recent literature to 121 emphasize more recent, independent markers such as B-type natriuretic peptide. 122 The emergence of "-omics" approaches, including proteomics and genomics, has potential 123 for improved prediction and treatment strategies in trauma care. Changes in urine peptide 124 patterns can provide valid insights into several organ systems (18,19). Biomarkers such as 125 AKI204, which is useful for predicting acute kidney injury (AKI) in ICU patients (20), and

126 CKD273, which is a biomarker for the detection of chronic kidney disease (CKD), can predict

127 worsening of kidney function (21) or cardiovascular outcome (22) and may be good

biomarkers for both predicting kidney damage in polytraumatized patients and providing the

time to start renal replacement therapy early (23,24). The COV50 classifier, developed

130 during the COVID-19 pandemic was able to predict the incidence of death and disease 131 progression in infected patients (25). It also demonstrated significant prediction of mortality in 132 patients without SARS-CoV-2 infection in the ICU but also in the general population (25,26). 133 These results support the hypothesis that urinary peptide-based biomarker classifiers 134 represent a significant advancement in the ability to monitor and manage complex 135 pathophysiological processes in polytraumatized patients. Therefore, the aims of this pilot 136 study were to examine whether trauma-specific peptides can be identified in urine samples 137 and whether urinary peptide-based classifiers may predict patient outcomes and organ 138 failure.

139 Methods

140 Cohort description

In this prospective nonrandomized pilot study, urinary proteomic data from 16 severely
injured patients recruited between January and July 2023 were examined. All adult patients
aged ≥18 years of both genders who had experienced primary trauma and were admitted to
our level 1 trauma center were included. Patients with direct traumatic consequences to the
urinary tract, bladder, or kidneys were excluded due to unpredictable analysis failure.
Treatment followed the current state of medical practice, in accordance with guidelines and
international standards.

Each patient was informed about the study and the procedure either immediately or after regaining consciousness and capacity. In the case of a caregiver situation, the caregiver was provided with appropriate information. Informed consent was obtained retrospectively once a caregiver was available or the capacity for consent was established. If retrospective inclusion in the study was undesirable, the patient's collected data were excluded. All participants provided written consent, and the study was approved by the Ethics Committee of Hannover Medical School (No: 10415_BO_S_2022).

155 The study was conducted in accordance with Good Clinical Practice and the Declaration of

- 156 Helsinki. According to the New Berlin score, 14 of the 16 patients met the criteria for
- polytrauma (19). These multiple-injury patients had an ISS \geq 16, at least two injuries with an
- AIS of \geq 3 and an indication for intensive care monitoring or surgery. The other two patients
- had a single injury requiring a longer hospital stay (e.g. vacuum sealing, external fixator,
- 160 extensive soft tissue damage) ensuring that the entire monitoring period was completed.

161 Urine sample and data collection

- 162 For all 16 patients, urine samples and data were collected in the department of Trauma
- 163 Surgery, Medical School of Hanover, Hanover, Germany. If a urinary catheter was inserted in
- the emergency room, the first urine sample was collected, as shown in the flow diagram
- 165 (Figure 1). Blood was also sampled according to polytrauma standards. If patients were
- directly admitted to the intensive care unit following admission to the emergency room, the
- 167 first urine sample was collected. According to the study design, urine was sampled on days
- 168 0, 2, 5, 10, and 14 using a urine monovette containing boric acid (Sarstedt, Nümbrecht,
- 169 Germany) and stored frozen at -20°C.
- 170 Figure 1: Collection of urine and blood samples and scoring



172 **Parameters**

173 On the days of urine collection, the patients were assessed using current intensive care

scores. On the day of admission, the ISS, TRISS, RISC II, APACHE-II, SAPS-II, and TIPS

175 scores were recorded. Since the extent of injury did not change, the ISS and TRISS were

176 only recorded at admission. APACHE-II was scored analogously on all sampling days, while

177 SAPS-II and TIPS were assessed once upon admission.

178 Blood samples were also taken on the sampling days. The samples were investigated for

electrolytes, lactate, CRP, complete blood count with haemoglobin and leukocytes,

180 coagulation parameters (INR, PTT), and kidney retention parameters.

181 Furthermore, the following events were recorded: Long-term ventilation, tracheotomy, prone

182 position, acute respiratory distress syndrome (ARDS), acute kidney failure, dialysis,

cardiovascular events, resuscitation, death, emergency surgery, extracorporeal membrane

184 oxygenation (ECMO), and early discharge from the ICU (**Supplementary Table 1**). The

185 combined endpoint was defined as death and/or kidney failure and/or respiratory

186 insufficiency.

187 **Proteomic analysis and data processing**

188 Urine sample preparation was performed as previously described (27). Briefly, the urine 189 samples were thawed immediately before use, and 0.1 ml of urine was diluted with 0.7 ml of 190 2 M urea and 10 mM NH4OH containing 0.02% SDS. The samples were ultrafiltered and 191 desalted using a PD-10 column (GE Healthcare, Danderyd, Sweden) equilibrated with 0.01% 192 NH4OH. The filtrate was lyophilized and stored at 4°C until Capillary electrophoresis-mass 193 spectrometry (CE-MS) analysis was performed. CE-MS analyses were performed on a 194 P/ACE MDQ capillary electrophoresis system (Beckman Coulter, Brea, California) coupled 195 on-line to a micrOTOF II mass spectrometer (Bruker Daltonic, Bremen, Germany) as 196 previously described (28).

- 197 The mass spectral peaks were deconvoluted using MosaFinder software (29). Normalization
- 198 was performed using a linear regression algorithm with internal standard peptides as
- 199 references. The detected peptides were deposited, matched, and annotated in the Microsoft
- 200 SQL database (Microsoft, Redmond, Washington, USA).

201 The amino acid sequences were obtained by performing MS/MS analysis using a P/ACE CE

202 coupled to a Q Exactive[™] Plus Hybrid Quadrupole-Orbitrap[™] MS instrument (Thermo

- 203 Fisher Scientific, Waltham, Massachusetts, USA). The mass spectrometer was operated in
- 204 data-dependent mode to automatically switch between MS and MS/MS acquisition. The data
- 205 files were searched against the UniProt human nonredundant database using Proteome
- 206 Discoverer 2.4 and the SEQUEST search engine without enzyme specification (activation
- 207 type: HCD; precursor mass tolerance: 5 ppm) ; fragment mass tolerance: 0.05 Da). The false
- discovery rate (FDR) was set to 1%. For further validation of the obtained peptide
- sequences, the correlation between peptide charge at a working pH of 2 and CE migration
- time was used to minimize false-positive derivation rates (30). The calculated CE migration

- 211 times of the sequence candidates based on their peptide sequences (number of basic amino
- acids) were compared to the experimental migration times.

213 Application of urine peptide-based biomarker classifiers

- 214 In this study, predefined urinary peptide-based classifiers for predicting the onset and
- 215 progression of CKD, AKI, and ARDS were used. For testing the endpoints, the classifiers
- 216 CKD273, AKI204, and Cov50 were applied. previously(19,20,31).

217 **Statistics**

- 218 Statistical analysis was performed using SPSS computer software (SPSS 28, IBM, Armonk,
- 219 New York, USA). Demographics, clinical variables, and proteomics classification scores are
- summarized as the means±SDs, and categorical variables are presented as frequencies (%).
- 221 Group means were compared using the Wilcoxon rank sum exact test, Fisher's exact test
- and Wilcoxon rank sum test.
- 223 The CE-MS-based data of 14 trauma patients and 14 sex- and age-matched healthy controls
- 224 extracted from the human urinary databasewere used to identify urinary peptides potentially
- associated with trauma (29). The statistical analysis was performed using R-based statistical
- software. Only peptides with a frequency threshold of at least 70% in one of the groups were
- 227 considered. P values were obtained using the Wilcoxon signed-rank test, followed by
- 228 Benjamini–Hochberg false discovery rate adjustment.

229 **Results**

230 Cohort characteristics

- 231 The patient characteristics of the whole cohort (n=16) are shown in **Table 1**. The average
- age of the study population was 46 ± 21 years. The mean ISS was 27 ± 15 , the average
- TRISS was 56 \pm 39, and the average RISC II score was 11 \pm 14. In **Table 2** mean AIS,
- 234 systolic blood pressure and ASA score (classification of patients regarding their physical

235	condition, American Society of Anesthesiologists) of the 14 polytraumatized patients are
236	shown. The mean AIS for the head, face, thorax, abdomen, extremities with pelvic injuries
237	and external injuries were 2.00±1.24, 0.64±0.84, 2.64±1.65, 2.00±1.74, 2.50±1.40 and
238	0.93±0,83, respectively, at admission. The mean systolic blood pressure was 133.93
239	mmHg±17.67 at admission. The average preclinical ASA score was 1.43. Upon admission,
240	the average SAPS II score was 32 (\pm 13), and the average TIPS score was 17.54 (\pm 9.46).

241 **Table 1:** Mean values for baseline cohort characteristics of all 16 patients included (14 polytrauma patients),

242

EP EP = Endpoint, *Wilcoxon rank sum exact test; Fisher's exact test; Wilcoxon rank sum test

Characteristic	Ν	Overall, N = 16	no EP, N = 9	EP, N = 7	p value*
Age (years), mean ± SD	16	46 ± 21	43 ± 15	49 ± 28	0.8
Female gender, n (%)		8 ± 50%	5 ± 56%	3 ± 43%	>0.9
Lactate (mmol/l), mean ± SD	14	2.76 ± 1.91	2.19 ± 1.59	3.33 ± 2.15	0.12
C-reactive protein <u>(mg/dl</u>), mean ± SD	16	3.1 ± 4.7	1.2 ± 0.8	5.5 ± 6.5	0.3
Haemoglobin (g/dl), mean ± SD	16	11.76 ± 2.54	11.83 ± 2.88	11.66 ± 2.24	>0.9
CKD273, mean ± SD	15	0.13 ± 0.64	-0.27 ± 0.61	0.58 ± 0.25	0.004
AKI_204, mean ± SD	15	-0.14 ± 0.92	-0.65 ± 0.91	0.45 ± 0.51	0.029
Cov50, mean ± SD	15	-0.14 ± 1.30	-0.80 ± 1.46	0.61 ± 0.45	0.094
APACHE 1.day, mean ± SD	14	12 ± 8	10 ± 10	14 ± 6	0.4
RISC II, mean ± SD	14	11 ± 14	7 ± 10	15 ± 16	0.4
ISS, mean ± SD	16	27 ± 15	22 ± 12	34 ± 17	0.3
TRISS, mean ± SD	15	56 ± 39	65 ± 39	45 ± 38	0.2
SAPS II, mean ± SD	14	32 ± 13	29 ± 16	35 ± 11	0.7
TIPS, mean ± SD	14	17 ± 10	12 ± 7	21 ± 10	0.13

244 Table 2: Mean values for AIS, systolic bloodpressure and ASA of all 14 polytraumatzed patients

Characteristics	Ν	mean	SD
Abbrevieated Injury Scale (AIS)	14	2,00	1,24

Head	14	0,64	0,84
Face	14	2,64	1,65
Thorax	14	2,00	1,74
Abdomen	14	2,50	1,40
Extremities, pelvis	14	0,93	0,83
External			
Systolic bloodpressure on admition (mmHg)	14	133,93	17,67
ASA	14	1,43	0,65

245

Trauma patient outcomes

246 Supplementary Table 1 lists the frequencies of injuries and recorded events during the 14-247 day monitoring period in the polytrauma patients (n=14). Eleven patients suffered from 248 traumatic brain injury (n=11), while one patients had spinal cord injury. Thoracic trauma was 249 present in 71% of the patients (n=10), and half of the patients had both abdominal trauma 250 (n=7) and pelvic injuries (n=7). The following events were observed during the study: 1 251 patient did not survive the study (7%). Four patients developed respiratory insufficiency 252 (29%), and an equal number of patients suffered acute kidney failure (29%), with 1 patient 253 requiring dialysis. ECMO support was necessary for one patient (7%). Additionally, one 254 patient needed to be placed in the prone position during intensive care (7%). ARDS developed in 1 patient (7%). Supplementary Table 2 shows the frequencies of successful 255 256 probe collection, score and bloodsample trends over the whole monitoring period of 14 days. 257 During the monitoring period, not all urine samples could be collected due to early discharge. 258 Eight patients completed the entire study in 14 days (57%). Despite early discharge and the 259 reduction in the number of patients from the third sampling point (Day 5), the average 260 APACHE II score showed no consistent trend over time (12.3 ±7.6, 11.2 ±6.0, 10.9 ±6.2, 12.1 261 ± 6.2 , 12.6 ± 6.6). In the laboratory results corresponding to the sampling days, the highest 262 average lactate levels were observed on the day of admission (2.8 mmol/l ±1.9). 263 Subsequently, there was a successive decrease, with normalization of the lactate levels on 264 the following sampling days (1.6 mmol/l ±1.6, 1.0 mmol/l ±0.4, 0.8 mmol/l ±0.3, 0.7 mmol/l 265 ±0.1).

On average, all included patients had normal CRP levels at admission (3.2 mg/dl ±1.9). At
sampling days 2 and 4, increases in the average values of 1695 mg/dl ±99.46 and 139.0

268 mg/dl ±166.64, respectively, were observed.

269 On the day of admission, the patients had an average Hb level of 11.7 g/dl ±2.7, which

- showed the greatest decrease at sampling day 2 (9.1 g/dl ±2.2) and then a successive mild
- decline at the remaining sampling days (9.0 g/dl ±1.7, 8.3 g/dl ±1.3, 8.9 g/dl ±0.9). During the
- 272 monitoring period, 3 patients did not require any packed red blood cells (PRBC) (21%), 1
- 273 patient received 4 PRBCs (7%), 4 patients each received 5 (29%), 2 patients required 7
- 274 (14%), another 2 patients received 12 (14%), and one patient required 36 while another
- 275 needed 57 PRBCs (7%).

276 **Definition of urinary peptides specific for polytrauma patients**

277 For the definition of urinary peptides significantly associated with trauma, the urinary peptide 278 data of 14 polytraumatized patients and 14 age- and sex-matched healthy controls from the 279 Human Urinary Peptide Database were used(32). This comparison revealed that 281 280 peptides were significantly affected (p<0.05, Wilcoxon test followed by adjustment for 281 multiple comparisons by Benjamini and Hochberg). All the identified peptides are listed in 282 **Supplementary Table 3.** We observed consistent upregulation of the expression of the 283 peptides Alpha-1-antitrypsin (A1AT) (n=3), Fetuin (FETUA) (n=3), and Myoglobin (MYG) 284 (n=2), which is in line with expectations and downregulation of the expression of fragments of 285 CD99 (n=9), PIGR (n=9) and UROM (n=6). One highly upregulated ProSAAS fragment was 286 also detected. Most of the significant peptides were fragments of different collagens (n=205), 287 118 of which were downregulated.

288 Application of urinary peptide-based classifiers and their

289 association with established severity scores

- 290 On the obtained CE-MS data, the previously developed classifiers CKD273, AKI204 and
- 291 CoV50 were applied. For each classifier and patient, the numeric classification score was
- 292 calculated.
- 293 The classifier for CKD prediction, CKD273, demonstrated a significant correlation with the
- ISS (p=0.034) and the APACHE-II score (p<0.001). The APACHE-II score was the only
- severity score that was obtained not only at baseline but also at every follow-up timepoint.
- 296 The AKI204 classifier correlated significantly (p=0.031) with the SAPS and APACHE-II score
- 297 (p<0.001). The Cov50 classifier was significantly correlated with the ISS (p=0.042), the RISC
- II (p=0.040) and the APACHE-II score (p<0.001). A chart of the correlation statistics is shown
- 299 in **Figure 2**.
- 300 Figure 2: Chart of correlation statistics between the clinical parameters, severity scores and peptide-based
- 301 classifiers.



302

303 Associations of the parameters with the combined endpoint

- 304 In the next step, the associations of clinical parameters, severity scores, and the obtained
- 305 peptide-based classification scores at baseline with the combined endpoint were
- investigated. The results are listed in **Table 1** and shown in the form of box-whisker plots in
- 307 Figure 3. Significant differences between the patients who reached the combined endpoint
- and those who did not were observed for CKD273 and AKI204 (p=0.004 and p=0.029),
- 309 where the Cov50 classifier showed only a trend (p=0.094). The clinical parameters and
- 310 severity scores did not significantly differ between the groups. Figure 4 displays the
- 311 classification scores of the peptide-based classifiers throughout the entire study period.







313

314 Box-whisker plots of the baseline parameters and their associations with the prediction of the combined endpoint

316

^{315 (}EP) are shown.

318

- 319 Figure 4: Distribution of classification scores obtained using the urinary peptide-based classifiers AKI204,
- 320 CKD273, and Cov50 between patients who reached the combined endpoint and those who did not throughout the
- 321 entire study duration.



322

323 **Discussion**

- 324 The aim of this study was to investigate whether
- 325 a) severely injured trauma patients exhibit significant deregulation of urinary peptides, and
- b) such changes can be used to predict outcomes and guide treatment.
- 327 The combined endpoints of the patients in this study were defined as death and/or kidney
- 328 failure and/or respiratory insufficiency.
- 329 As hypothesized, our data demonstrated a highly significant deregulation of urinary proteom
- levels in trauma patients. A significant change was observed in CKD273 (p = 0.004) and in
- 331 AKI_204 (p = 0.029). Cov50 showed a weak trend (p = 0.094).
- 332 These urine proteomes were initially used for predicting acute or acute-on-chronic kidney
- failure (AKI_207, CKD237) and the development of adverse outcomes in COVID-19 patients
- (Cov50) (20-22,33-35). Only one patient (7,1%) developed ARDS in this small cohort, which
- could explain the non-significant trend in Cov50 (p = 0.094). In contrast, four patients
- 336 experienced acute kidney failure, and one patient required dialysis

337 Overall, 281 deregulated peptides were observed among the polytrauma patients. Among 338 the measured peptides, the most notable changes were observed in collagen peptides 339 (Supplementary Table 3). This was expected, as collagen peptides are the most abundant 340 peptides in urine and are influenced by several pathologies, including kidney and 341 cardiovascular diseases, as well as death (30). As shown here, the effect on collagen 342 peptides was inconsistent across these pathologies; some peptides were significantly 343 upregulated, while others were highly significantly and consistently reduced (Supplementary 344 **Table 3**). Although these peptides are very common, the molecular mechanisms underlying 345 their regulation and their connection to (patho)physiology remain unknown.

346 Kidney failure:

347 Alpha-1-antitrypsin and Fetuin showed significant deregulations (**Supplementary Table 3**).

348 Similar changes have been observed previously in patients with chronic or acute kidney

diseases, likely indicating severe renal stress in trauma patients (22,28,33). Stress or

350 damage to the kidney is further indicated by the consistent reduction of uromodulin

351 fragments (36). Additional consistent and prominent changes include the reduction of

352 fragments of CD99 and the polymeric immunoglobulin receptor (37). Such changes have

also been observed in connection with severe/lethal courses of COVID-19 and have been

interpreted as possible indications of endothelial damage (30,34-37).

355 There are numerous efforts to predict acute kidney injury in both medically ill and severely 356 injured patients(38). Many functional tests aim to make predictions not through the 357 quantification of laboratory chemical parameters, but through the performance of urine output 358 after stress tests, such as the furosemide stress test or renal functional reserve(38). The 359 standardized furosemide stress test has a good predictive probability (AUC 0.87, p = 0.001) 360 in a limited test group, but the testing requires a coordinated timing of furosemide 361 administration and documentation of time and urine output(39). This must be accommodated 362 within the time-intensive care of critically ill patients(40).

363 Genetic variations as determinants for both risk and outcome are not well defined(41). 364 Association studies have identified a large number of genetic polymorphisms that are 365 capable of predicting different and variable kidney responses to the same type of injury(41). 366 However, identifying these individual genetic susceptibilities for AKI plays no role in 367 managing acute courses in previously healthy, severely injured patients, or in prognostic 368 assessment and therapy timing. Overall, the results of such models are variable and often 369 inconsistent. The lack of robust and reproducible associations with AKI is not surprising given 370 the complex, multifactorial nature of chronic and acute renal insufficiency(38). None of these 371 studies combined the prognostic information from potential genetic polymorphisms with 372 existing prediction models(38). Ideal models for such clinical studies continue to be applied in 373 elective cardiac surgery (42). The reason for this is that cardiac surgical procedures not only 374 represent a large surgical population but also have a well-studied epidemiology of AKI in this 375 context, due to the use of heart-lung machines and the resultant potential ischemia-376 reperfusion injury to the kidney (42). However, this population cannot in any way reflect 377 patients who suffer not only massive musculoskeletal damage but also direct injuries to the 378 kidney

Severely injured patients with preclinical shock due to hemorrhage and extensive extremity trauma with muscle damage often suffer from kidney damage, which frequently leads to acute renal failure requiring dialysis (43). The need for a predictive tool is substantial, as the prediction and estimation of interventions such as dialysis in the daily routine of intensive care are not currently predicted by injury or mortality scores (ISS, TRISS, RISC II) or by progression assessments such as the APACHE II score. These outcomes still depend on the rapid detection of the condition and the continuous, rigorous monitoring of patients (44).

In our patient cohort, 4 patients (29%) showed acute kidney injury. This pilot study showed a significant prediction probability for the development of acute kidney injury in polytraumatized patients [CKD273 (p = 0.004) and AKI_204 (p = 0.029)].

389 **ARDS**:

390	Regarding ARDS and estimating interventions such as prone positioning or ECMO, we face
391	a similar peptide deregulations to AKI (Supplementary Table 3). Papurica et al. and Cao et
392	al. demonstrated a wide range of ARDS-relevant genes and factors (45,46). Cao et al.
393	developed a promising prediction model that could improve early clinical management and
394	intervention in the development of ARDS (46). However, one of the main problems in
395	analyzing genes and microRNAs as predictive tools is the lack of standardization of methods
396	for extraction, quantification, and data analysis (46). In contrast, the handling of urinary
397	samples does not present major challenges, as it is an excretory product without special
398	demands in terms of purity and concentration, making it easily obtainable (22,33,37).
399	In clinical practice, the Berlin Definition is currently used as the gold standard for ARDS
400	treatment (47). It relies on various criteria that must be fulfilled to make a diagnosis (47). The
401	severity of ARDS is determined based on the ratio of arterial oxygen partial pressure to
402	fractional inspired oxygen (PaO2/FiO2), with different levels established depending on the
403	measured values (47). The appearance of these criteria and the rise in the required oxygen
404	partial pressure can sometimes occur days later (47). Often, clinicians are confronted with
405	the clinical picture of ARDS unexpectedly. The silent period before onset can lead to an
406	irreversible spiral, and interventions may be decided too late as a response (47).
407	ARDS is characterized by severe hypoxemia due to non-cardiogenic pulmonary edema (48).
408	Both COVID-19 and ARDS frequently exhibit diffuse alveolar damage, which is marked by

the destruction of the alveolar-capillary barrier (48). The presence of non-cardiogenic
pulmonary edema is a hallmark of ARDS and is also observed in severe COVID-19 cases

411 (49-51). Both conditions involve a hyperactive inflammatory response (48). In COVID-19, this

412 is often referred to as a "cytokine storm," where excessive inflammatory cytokines cause

413 extensive lung damage, similar to what is seen in ARDS(48). Although there are similar

expressions in both diseases, the pathophysiology of COVID-19 differs from ARDS due to its
diverse complexity(48,49).

416	Some severe COVID-19 cases develop classical ARDS, but a considerable portion of severe
417	cases do not conform to the classical ARDS characteristics of "reduced lung volume and
418	decreased compliance"(48-52). In these patients, pulmonary compliance is nearly normal,
419	which is not consistent with the severity of hypoxemia(53). Furthermore, ARDS-related
420	hypoxemia is mainly caused by intrapulmonary shunts, supplemented by dead space
421	ventilation(54). COVID-19-related hypoxemia may be explained by a dysfunction of hypoxic
422	pulmonary vasoconstriction, leading to a loss of lung perfusion regulation and pulmonary
423	microthrombi(53,55).

424 Although the courses of Covid-19 and classical ARDS differ in some pathophysiological 425 aspects, they do have similarities. Especially through the development of ARDS in severe 426 Covid cases, these adverse outcomes can be identified by the urinary proteomic COV50 427 marker. In our study, out of 10 (71,4%) patients with thoracic trauma, 4 developed respiratory 428 insufficiency (28,6%), of which only one patient manifested ARDS (7,1). The COV50 showed 429 only a trend in predicting these endpoint (p = 0.094). To better assess the suitability of this 430 urinary proteome, a larger number of patients need to be included compared to this pilot 431 study.

Due to the small number of patients and low manifestation of ARDS at the time of the pilot study, no reliable statements could be made for prognostic assessment, treatment interventions, and intervention timing, such as determining when ECMO (7,1%) or prone positioning (7,1%) is temporally indicated. Nevertheless, considering the trend of COV50 alongside other proteomic results, it appears to be a promising avenue to address these exact issues in the management of severe ARDS cases.

438 **Scores**:

439 The ISS is calculated by squaring the three highest values of the AIS and then adding them 440 together (56). It is used to quantify and assess the overall injury severity of a patient based 441 on injuries in different body regions (56). However, the ability to determine injury severity 442 based on the discriminative abilities of an ISS threshold depends on a reproducible definition 443 of "severe" (57). The ISS is highly dependent on the person collecting the data (58). 444 Experienced individuals have recorded significantly higher values (58). This inter-observer 445 variability often makes the score's interpretation challenging and less explicit. Evaluating the 446 severity of an injury (i.e., direct acute impact, excluding effects of comorbidities, 447 complications, and treatments) depends on the specific aspects of the illness being 448 considered (57). This evaluation can involve various parameters, such as the likelihood of 449 death, the complexity and extent of required treatments and resources, the probability and 450 degree of permanent impairment, and the impact on the patient's quality of life (57). 451 Accordingly, in this study, we see no significant prediction of an endpoint by the ISS (p =452 0.3). The TRISS optimizes the prediction probability and, as a combination score of the RTS 453 and ISS, provides a probability of survival (59). Although historical literature shows alignment 454 with expected predictions, our study found no significance in predicting any endpoint (p =455 0.2). There is also criticism of the score, as the variables may not capture the full complexity 456 of the patient's condition (60).

457 Another approach to improving the prediction of survival probability in polytraumatized 458 patients is the RISC II, which includes not only anatomical injury descriptions but also 459 (patho)physiological indicators (26,57). By incorporating these discriminators, the score aims 460 to estimate the risk of death in severely injured patients more effectively (26). Integrating the 461 RISC II into daily intensive care practice, especially as a tool for monitoring the course of the 462 disease, is significantly challenging due to its difficult accessibility and determination, as the 463 score is primarily designed for initial survival probability assessment (26). Table 1 also shows 464 no significant prediction probability for the endpoints with the RISC II (p = 0,4).

Scores specifically designed and expanded for the intensive care unit promise better predictive accuracy for critical courses. The APACHE II score, in addition to parameters from individual organ systems, incorporates age, current clinical findings, and medical history to provide a scoring system for assessing critically ill patients, allowing daily predictions about survival probability (1,17,60). Neither on the first day nor throughout the entire sampling period did the APACHE II score show a significant predictive accuracy for any endpoint in this study (p = 0.4) (Table 1, Figure 3).

472 The SAPS II provides an assessment of the risk of death and is a tool for predicting the 473 intensive care trajectory of critically ill patients (13). The primary admission diagnosis does 474 not need to be entere (13). The severity of multiple injuries does not influence the predictive 475 accuracy (13). This is confirmed in our research question. The SAPS II score shows no 476 significance in predicting the endpoint (p = 0.7). These results are in line to other 477 retrospective multicenter studies, stating the APACHE II score and the SAPS II score did not 478 show acceptable performance in predicting outcomes for intensive care trauma patients (60). 479 Only the APACHE III score was reliable and is still frequently used in daily intensive care 480 medicine (61). However, the score requires additional software support that compares the 481 entered data with historical benchmark data from U.S. hospitals (61).

In our pilot study, none of the established scores showed a significant association with the combined endpoint. This is likely due to the limited power of the study. However, two of the urinary peptide classifiers, AKI204 and CKD273, significantly predicted the outcome (p =0.029, p = 0.004).

Nevertheless, these scores are a gold standard in their respective areas of use and are
employed daily in the assessment and care of severely injured and critically ill intensive care
patients. In addition to predicting acute kidney injury, CKD273 significantly correlates with the
ISS and its associated assessment of the severity of patients' injuries (p = 0.034). Likewise,
CKD273 shows a correlation with the APACHE II-Score, which was the only score collected

491 at all sampling points and provides an estimate of the progression (p < 0.001). AKI 207 also 492 showed a significant correlation with scores for the assessment of intensive care patients 493 and their progression. The classifier correlated with the SAPS II (p = 0.031) and the APACHE 494 II score (p < 0.001) and could provide an outlook on the intensive care course and care 495 requirements. Similar to CKD273, Cov50 also showed a significant correlation with the ISS (p 496 = 0.042), as well as with the RISC II (p = 0.040) and the APACHE II-Score (p < 0.001). Thus, 497 Cov50 could also serve as a classifier for the primary assessment of injury severity and the 498 resulting mortality risk.

499 *Limitations:*

500 This study has several limitations. First, the sample size was small, with a total of 16 patients 501 and only 14 with polytrauma; thus, this study was designed as a pilot study. Additionally, the 502 complete set of samples (14 days, 5 samples per patient) could only be collected from 8 503 patients. Furthermore, there were some heterogeneous samples. Due to the small number of 504 patients, the study population exhibited a highly heterogeneous pattern of injuries and injury 505 severity. Furthermore, not all relevant laboratory values could be collected on all sampling 506 days. Additionally, there are challenges in data collection once patients are transferred from 507 the ICU to the general ward.

508 Conclusion

The prediction of severe organ damage/organ failure and their critical courses in severely injured patients is still associated with high uncertainty due to individual patterns of injury and progression. The prediction of these events is frequently based on the expertise and experience of the intensivist, with frequent laboratory tests and close monitoring of important organ systems, such as the liver, kidneys, heart, and lungs, required to prepare for unexpected courses and indications for interventions. Nonetheless, intensive care physicians are often faced with unforeseen developments.

- 516 This pilot study should serve as a proof of concept for applying proteome analysis in
- 517 traumatology, paving the way for a multicenter study, as a significantly greater number of
- 518 cases is required for a conclusive evaluation of the investigated biomarkers.

519 List of abbreviations

- 520 AIS Abbreviated injury scale
- 521 AKI acute kidney injury
- 522 APACHE II acute physiology and chronic health evaluation II
- 523 ARDS acute respiratory distress syndrome
- 524 CE-MS Capillary electrophoresis–mass spectrometry
- 525 CKD Chronic kidney disease
- 526 CRP C-Reaktive Protein
- 527 ECMO extracorporeal membrane oxygenation
- 528 FDR false discovery rate
- 529 GCS Glasgow coma scale
- 530 Hb Haemoglobin
- 531 ICU intensive care unit
- 532 ISS injury severity score
- 533 MODS multiple organ dysfunction syndrome
- 534 MOD multiorgan dysfunction
- 535 MOF multiorgan failure
- 536 SOFA sequential organ failure assessment
- 537 NT-proBNP N-terminal prohormone of brain natriuretic peptide

- 538 PRBCs packed red blood cells
- 539 PTT partial thromboplastin time
- 540 RISC revised injury severity classification
- 541 RTS revised trauma score
- 542 SAPS II simplified acute physiology score
- 543 TISS therapeutic intervention scoring system
- 544 TRISS trauma and injury severity score

545

546 **References**

- 547 (1) Lambden S, Laterre PF, Levy MM, Francois B. The SOFA score—development, utility
- and challenges of accurate assessment in clinical trials. Critical Care 2019 Nov

549 27,;23(1):374.

- 550 (2) Balogh ZJ. Polytrauma: It is a disease. Injury 2022 Jun;53(6):1727-1729.
- (3) Rossaint R, Afshari A, Bouillon B, Cerny V, Cimpoesu D, Curry N, et al. The European
- 552 guideline on management of major bleeding and coagulopathy following trauma: sixth
- edition. Critical care (London, England) 2023 Mar 1,;27(1):80.
- 554 (4) van Breugel JMM, Niemeyer MJS, Houwert RM, Groenwold RHH, Leenen LPH, van
- 555 Wessem KJP. Global changes in mortality rates in polytrauma patients admitted to the ICU-a
- 556 systematic review. World journal of emergency surgery 2020 Sep 30,;15(1):55.
- 557 (5) Hutchings L, Watkinson P, Young JD, Willett K. Defining multiple organ failure after major
- trauma: A comparison of the Denver, Sequential Organ Failure Assessment, and Marshall
- scoring systems. The journal of trauma and acute care surgery 2017 Mar;82(3):534-541.

- 560 (6) Kroupa J. Definition of "polytrauma" and "polytraumatism". Acta chirurgiae orthopaedicae
- 561 et traumatologiae Čechoslovaca 1990 July;57(4):347-360.
- 562 (7) Lichte P, Lefering R, Marzi I, Bouillon B, Peitzman A, Balogh Z, et al. Neudefinition des
- 563 Polytraumas ("Berlin Definition") anhand des Traumaregister DGU® Ergebnis eines
- internationalen Konsensprozesses. 2014 Oct 13,.
- 565 (8) Cohen IL. Definitions for Sepsis and Organ Failure: The ACCP/SCCM Consensus
- 566 Conference Committee Report. 1993 Feb 1,;103(2):656.
- 567 (9) Sauaia A, Moore EE, Johnson JL, Chin TL, Banerjee A, Sperry JL, et al. Temporal trends
- of postinjury multiple-organ failure: still resource intensive, morbid, and lethal. 2014
- 569 Mar;76(3):582-593.
- 570 (10) Cole E, Gillespie S, Vulliamy P, Brohi K, Akkad H, Apostolidou K, et al. Multiple organ
- 571 dysfunction after trauma. 2020 Mar;107(4):402-412.
- 572 (11) ZYGUN DA, LAUPLAND KB, FICK GH, SANDHAM JD, DOIG CJ. Limited ability of
- 573 SOFA and MOD scores to discriminate outcome : a prospective evaluation in 1,436 patients.
- 574 2005 Mar 1,;52(3):302-308.
- 575 (12) KNAUS WA, DRAPER EA, WAGNER DP, ZIMMERMAN JE. APACHE II: A severity of
- 576 disease classification system. 1985 Oct;13(10):818-829.
- 577 (13) Le Gall JR. A new Simplified Acute Physiology Score (SAPS II) based on a
- 578 European/North American multicenter study. 1993 Dec 22,;270(24):2957-2963.
- 579 (14) Singh J, Gupta G, Garg R, Gupta A. Evaluation of trauma and prediction of outcome
- using TRISS method. 2011 Oct;4(4):446-449.

- 581 (15) Lefering R, Huber-Wagner S, Nienaber U, Maegele M, Bouillon B. Update of the trauma
- risk adjustment model of the TraumaRegister DGU[™]: the Revised Injury Severity
- 583 Classification, version II. 2014 Sep 5,;18(5):476.
- 584 (16) Rau C, Wu S, Kuo P, Chen Y, Chien P, Hsieh H, et al. Polytrauma Defined by the New
- 585 Berlin Definition: A Validation Test Based on Propensity-Score Matching Approach. 2017

586 Sep 01,;14(9).

- 587 (17) Sudhakaran S, McCullough PA. Common laboratory parameters as indicators of
- multi □ organ dysfunction in acute heart failure. 2019 Jun;21(6):751-753.
- 589 (18) Bannaga AS, Metzger J, Kyrou I, Voigtländer T, Book T, Melgarejo J, et al. Discovery,

validation and sequencing of urinary peptides for diagnosis of liver fibrosis—A multicentre

591 study. 2020 Dec 1,;62:103083.

592 (19) Wendt R, Thijs L, Kalbitz S, Mischak H, Siwy J, Raad J, et al. A urinary peptidomic

profile predicts outcome in SARS-CoV-2-infected patients. 2021 Jun 01,;36:100883.

594 (20) Piedrafita A, Siwy J, Klein J, Akkari A, Amaya-Garrido A, Mebazaa A, et al. A universal

595 predictive and mechanistic urinary peptide signature in acute kidney injury. 2022 Nov596 7,;26(1):344.

597 (21) Rodríguez-Ortiz ME, Pontillo C, Rodríguez M, Zürbig P, Mischak H, Ortiz A. Novel

598 Urinary Biomarkers For Improved Prediction Of Progressive eGFR Loss In Early Chronic

- 599 Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease. 2018
- 600 Oct 29,;8(1):15940-11.

(22) Verbeke F, Siwy J, Van Biesen W, Mischak H, Pletinck A, Schepers E, et al. The urinary
proteomics classifier chronic kidney disease 273 predicts cardiovascular outcome in patients
with chronic kidney disease. 2021 Apr 26,;36(5):811-818.

604	(23) Pontillo C, Zhang Z, Schanstra JP, Jacobs L, Zürbig P, Thijs L, et al. Prediction of
605	Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker. 2017 Nov
606	1,;2(6):1066-1075.
607	(24) Critselis E, Lambers Heerspink H. Utility of the CKD273 peptide classifier in predicting
608	chronic kidney disease progression. 2016 Feb 1,;31(2):249-254.
609	(25) Latosinska A, Siwy J, Cherney DZ, Perkins BA, Mischak H, Beige J. SGLT2 Inhibition
610	reverts urinary peptide changes associated with severe COVID□19: An in□silico
611	proof of principle of proteomics based drug repurposing. 2021 Oct;21(20):e2100160-n/a.
612	(26) Nkuipou-Kenfack E, Latosinska A, Yang W, Fournier M, Blet A, Mujaj B, et al. A novel
613	urinary biomarker predicts 1-year mortality after discharge from intensive care. 2020 Jan
614	9,;24(1):10.

(27) Mischak H, Vlahou A, Ioannidis JPA. Technical aspects and inter-laboratory variability in
native peptide profiling: The CE–MS experience. 2013 Apr;46(6):432-443.

617 (28) Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, et al. Discovery and

validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet
Oncol. 2006 Mar;7(3):230-240.

(29) Latosinska A, Siwy J, Mischak H, Frantzi M. Peptidomics and proteomics based on
CE MS as a robust tool in clinical application: The past, the present, and the future. 2019
Sep;40(18-19):2294-2308.

(30) Zürbig P, Renfrow MB, Schiffer E, Novak J, Walden M, Wittke S, et al. Biomarker
discovery by CE-MS enables sequence analysis via MS/MS with platform-independent
separation. 2006 Jun 1,;27(11):2111-2125.

626	(31) Good DM, Zürbig P, Argilés À, Bauer HW, Behrens G, Coon JJ, et al. Naturally
627	Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease. 2010
628	Nov 1,;9(11):2424-2437.
629	(32) Latosinska A, Frantzi M, Siwy J. Peptides as "better biomarkers"? Value, challenges,
630	and potential solutions to facilitate implementation. 2023 Jun 26,.
631	(33) Tofte N, Lindhardt M, Adamova K, Bakker SJL, Beige J, Beulens JWJ, et al. Early
632	detection of diabetic kidney disease by urinary proteomics and subsequent intervention with
633	spironolactone to delay progression (PRIORITY): a prospective observational study and
634	embedded randomised placebo-controlled trial. Lancet Diabetes Endocrinol. 2020
635	Apr;8(4):301-312.
636	(34) Batra R, Uni R, Akchurin OM, Alvarez-Mulett S, Gómez-Escobar LG, Patino E, et al.
637	Urine-based multi-omic comparative analysis of COVID-19 and bacterial sepsis-induced
638	ARDS. 2022 Aug 10,.
639	(35) Li Y, Wang Y, Liu H, Sun W, Ding B, Zhao Y, et al. Urine proteome of COVID-19
640	patients. 2020;2:1-8.

- (36) LaFavers K, Garimella PS. Uromodulin: more than a marker for chronic kidney disease
 progression. 2023 May 1,;32(3):271-277.
- 643 (37) Øvrehus MA, Zürbig P, Vikse BE, Hallan SI. Urinary proteomics in chronic kidney
- disease: diagnosis and risk of progression beyond albuminuria. 2015 Aug 7,;12(1):21.
- (38) Simona Pozzoli, Marco Simonini, Paolo Manunta. Predicting acute kidney injury: current
 status and future challenges. 2017 -06-17;31(2):209-223.
- (39) Chawla LS, Davison DL, Brasha-Mitchell E, Koyner JL, Arthur JM, Shaw AD, et al.
- 648 Development and standardization of a furosemide stress test to predict the severity of acute
- 649 kidney injury. 2013;17:1-9.

(40) Koyner JL, Davison DL, Brasha-Mitchell E, Chalikonda DM, Arthur JM, Shaw AD, et al.
Furosemide stress test and biomarkers for the prediction of AKI severity. 2015;26(8):20232031.

(41) Lu JC, Coca SG, Patel UD, Cantley L, Parikh CR. Searching for genes that matter in

acute kidney injury: a systematic review. 2009;4(6):1020-1031.

655 (42) Emerging concepts in acute kidney injury following cardiac surgery. Seminars in

656 cardiothoracic and vascular anesthesia: SAGE Publications Sage CA: Los Angeles, CA;

657 2008.

(43) Muhamedhussein MS, Manji M, Nungu KS, Ruggajo P, Khalid K. Prevalence and risk

659 factors of acute kidney injury in polytrauma patients at Muhimbili Orthopedic Institute,

660 Tanzania. 2021 Mar 1,;11(1):74-78.

(44) Ivan MV, Rogobete AF, Bedreag OH, Papurica M, Popovici SE, Dinu A, et al. New

Molecular and Epigenetic Expressions as Novel Biomarkers in Critically III Polytrauma

Patients with Acute Kidney Injury (AKI). 2018 Jan 1,;64(5):663-668.

(45) Papurica M, Rogobete AF, Cradigati CA, Sarandan M, Dumache R, Bratu LM, et al.

665 Using the Expression of miRNAs as Biomarkers for the Evaluation Acute Respiratory

Distress Syndrome in the Critically III Polytrauma Patient. 2016 Jan 1,;62(8):1405-1411.

(46) Cao S, Li H, Xin J, Jin Z, Zhang Z, Li J, et al. Identification of genetic profile and

biomarkers involved in acute respiratory distress syndrome. Intensive Care Med2024;50(1):46-55.

670 (47) Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al.

Acute Respiratory Distress Syndrome: The Berlin Definition. 2012 Jun 20,;307(23):2526-

672 2533.

- 673 (48) Lu S, Huang X, Liu R, Lan Y, Lei Y, Zeng F, et al. Comparison of COVID-19 Induced
- 674 Respiratory Failure and Typical ARDS: Similarities and Differences. 2022 May 27,;9:829771.
- (49) Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. COVID-19 does
- not lead to a "typical" acute respiratory distress syndrome. 2020;201(10):1299-1300.
- (50) Xie Y, Wang X, Yang P, Zhang S. COVID-19 complicated by acute pulmonary
- 678 embolism. 2020;2(2):e200067.
- (51) Maiolo G, Collino F, Vasques F, Rapetti F, Tonetti T, Romitti F, et al. Reclassifying acute
- 680 respiratory distress syndrome. 2018;197(12):1586-1595.
- (52) Maunder RJ, Shuman WP, McHugh JW, Marglin SI, Butler J. Preservation of normal
- lung regions in the adult respiratory distress syndrome: analysis by computed tomography.
- 683 JAMA 1986;255(18):2463-2465.
- (53) Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L, et al. COVID-19
- 685 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med.
- 686 2020;46:1099-1102.
- (54) Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA
 2020;323(22):2329-2330.
- 689 (55) Xie Y, Wang X, Yang P, Zhang S. COVID-19 complicated by acute pulmonary
- embolism. 2020;2(2):e200067.
- (56) BAKER S, O NEILL B, HADDON W, LONG W. THE INJURY SEVERITY SCORE: A
- 692 METHOD FOR DESCRIBING PATIENTS WITH MULTIPLE INJURIES AND EVALUATING
- 693 EMERGENCY CARE. 1974 Mar;14(3):187-196.
- 694 (57) Palmer C. Major trauma and the injury severity score--where should we set the bar?
- 695 Annu.Proc.Assoc.Adv.Automot Med. 2007;51:13-29.

- (58) Waydhas C, Nast-Kolb D, Trupka A, Kerim-Sade C, Kanz G, Zoller J, et al. Trauma
- 697 scores: reproducibility and reliability. 1992 Feb;95(2):67-70.
- (59) Martens DS, Thijs L, Latosinska A, Trenson S, Zhang Z, Wang C, et al. SSRN-
- 699 id3854583.
- (60) Vassar MJ, Lewis FR, Chambers JA, Mullins RJ, O'Brien PE, Weigelt JA, et al.
- 701 Prediction of Outcome in Intensive Care Unit Trauma Patients: A Multicenter Study of Acute
- 702 Physiology and Chronic Health Evaluation (APACHE), Trauma and Injury Severity Score
- (TRISS), and a 24-Hour Intensive Care Unit (ICU) Point System. 1999 Aug;47(2):324-329.
- (61) Markgraf R, Deutschinoff G, Pientka L, Scholten T, Lorenz C. Performance of the score
- systems Acute Physiology and Chronic Health Evaluation II and III at an interdisciplinary
- intensive care unit, after customization. 2001 Jan 1,;5(1):31-36.

707

708 Supplementary Data

- 709 Supplementary Table 1: Frequencies of injuries and events in the 14 polytrauma patients in the
- 710 cohort during the 14-day monitoring period

Characteristics	Frequency	Percentage
		/11
	(N)	710
Traumatic brain injurie	11	78.6
	11	70.0
Spinal cord injurie	1	7 1
	•	714
Thoracic iniurie	10	71.4
		715
Abdominal iniurie	7	50
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		716
Pelvic injurie	7	50
		717
Respiratory insufficiency	4	28.6
		718
ARDS	1	7.1
		719
Prone position	1	7.1 1
		720
ECMO	1	7.1 - 20
		aa 721
Akute kidney injurie	4	28.621
Distais	4	722
Dialysis	1	7.7
Cardiovacaular Event	0	0723
	0	0, =0
Pesuscitation	0	0724
	0	0, = .
Death	1	7 1725
Douit	•	/ . P = -
Monitoring of 14 days completed	8	57.726
	Ŭ	0=0
Early discharge	6	42.9/27
,	-	

728

729 **Supplementary Table 2:** Frequencies of successful sample collection, score and blood

sample trends during the monitoring period of 14 days

Characteristics	Total	Frequency	Percentage
1. Sample collection on admission	14	14	100
2. Sample collection on day 2	14	14	100
3. Sample collection on day 5	14	12	85,7
4. Sample collection on day 10	14	9	64,3
5. Sample collection on day 14	14	8	57,1
Characteristics	Total	Mean	SD
1. APACHE II score on admission	14	12,29	7,64
2. APACHE II score on day 2	14	11,21	6,02
3. APACHE II score on day 5	12	10,92	6,24
4. APACHE II score on day 10	9	12,11	6,21
5. APACHE II score on day 14	8	12,57	7,66
1. Lactate on admission	14	2,76	1,91
2. Lactate on day 2	13	1,59	1,59
3. Lactate on day 5	10	0,96	0,35
4. Lactate on day 10	5	0,82	0,27
5. Lactate on day 14	3	0,73	0,12
1. CRP on admission	14	3,20	5,02
2. CRP on day 2	14	169,48	99,46
3. CRP on day 5	13	104,01	90,20
4. CRP on day 10	9	138,98	166,64
5. CRP on day 14	7	56,39	38,97
1. Hb on admission	14	11,69	2,66
2. Hb on day 2	14	9,06	2,18
3. Hb on day 5	13	9,02	1,71
4. Hb on day 10	9	8,32	1,32
5. Hb on day 14	7	8,89	0,88

731

732 **Supplementary Table 3**: Urinary peptides significantly different in abundance between

733 healthy controls and trauma patients (N=16 each) (.xls)